Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Defining the link between CDK2 activity and lineage-specific cancer susceptibility to RB loss

EF 2019-20

Résumé
"Gene defects that are oncogenic in one lineage are impotent in another. Understanding these dramatic differences in cancer susceptibility could expose new therapeutic vulnerabilities. RB is frequently mutated in retinoblastoma and small cell lung cancer (SCLC). Our group found that while murine RB-deficient retina exhibits many cancer hallmarks, only cell cycle length distinguishes the cancer prone lineage. Thus, in cancer-prone amacrine cells it was half that of resistant Müller glia. Remarkably, this was recapitulated in RB-null lung, where cell cycle length in cancer-prone pulmonary neuroendocrine cells (PNECs) was half that of resistant alveolar type II (AT2) cells. Moreover, lowering Cyclin Dependent Kinase 2 (CDK2) activity doubled cell cycle length and inhibited cancer initiation. My goal is to deduce when CDK2 confers cancer susceptibility. In cell lines, CDK2 activity peaks at G2/M, then dips dramatically at the start of G1. Cells with a shallow CDK2 activity trough in G1 re-enter the cell cycle. I hypothesize that higher CDK2 activity in the G1 trough also distinguishes cancer-prone from cancer-resistant RB-deficient lineages.. To test my hypothesis, I am exploiting a live CDK2 sensor. I validated this tool in retinoblastoma and SCLC cells. I will track CDK2 activity both in RB-deficient murine retinal cells, and in human embryonic stem cell derived lung organoids. I predict that the G1 CDK2 trough will be lower in cancer-resistant Müller/AT2 cells and higher in cancer-prone amacrine/PNECs. The systems I develop will expose CDK2 activity throughout the cell cycle, and define models to pursue critical CDK2 targets. By defining the mechanism of cancer susceptibility or resistance my work could lead to new therapies for SCLC and other RB null cancers. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428930
Name
Lai Christian C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining the link between CDK2 activity and lineage-specific cancer susceptibility to RB loss
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Susceptibility; Cdk2 Activity; Cell Cycle Length; Human Embryonic Stem Cells; Live Cdk2 Sensor; Lung Organoids; Retinoblastoma; Small Cell Lung Cancer
Abstract
"Gene defects that are oncogenic in one lineage are impotent in another. Understanding these dramatic differences in cancer susceptibility could expose new therapeutic vulnerabilities. RB is frequently mutated in retinoblastoma and small cell lung cancer (SCLC). Our group found that while murine RB-deficient retina exhibits many cancer hallmarks, only cell cycle length distinguishes the cancer prone lineage. Thus, in cancer-prone amacrine cells it was half that of resistant Müller glia. Remarkably, this was recapitulated in RB-null lung, where cell cycle length in cancer-prone pulmonary neuroendocrine cells (PNECs) was half that of resistant alveolar type II (AT2) cells. Moreover, lowering Cyclin Dependent Kinase 2 (CDK2) activity doubled cell cycle length and inhibited cancer initiation. My goal is to deduce when CDK2 confers cancer susceptibility. In cell lines, CDK2 activity peaks at G2/M, then dips dramatically at the start of G1. Cells with a shallow CDK2 activity trough in G1 re-enter the cell cycle. I hypothesize that higher CDK2 activity in the G1 trough also distinguishes cancer-prone from cancer-resistant RB-deficient lineages.. To test my hypothesis, I am exploiting a live CDK2 sensor. I validated this tool in retinoblastoma and SCLC cells. I will track CDK2 activity both in RB-deficient murine retinal cells, and in human embryonic stem cell derived lung organoids. I predict that the G1 CDK2 trough will be lower in cancer-resistant Müller/AT2 cells and higher in cancer-prone amacrine/PNECs. The systems I develop will expose CDK2 activity throughout the cell cycle, and define models to pursue critical CDK2 targets. By defining the mechanism of cancer susceptibility or resistance my work could lead to new therapies for SCLC and other RB null cancers. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lai, Christian C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~